CCK-BR Activators
CCK-BR (Cholecystokinin B Receptor) activators comprise a diverse group of chemical compounds that directly enhance the functional activity of this receptor. These activators can be classified into two main categories: endogenous ligands and synthetic agonists. Endogenous ligands such as Gastrin, Cholecystokinin (CCK), and Bombesin directly engage with CCK-BR, initiating intracellular signaling cascades that modulate receptor activity. Additionally, synthetic agonists like JMV-180 and SR 146,131 are designed to selectively activate CCK-BR, providing valuable tools for studying the receptor's specific functions. Another category includes compounds like Carbachol and Pentagastrin, which mimic the action of endogenous ligands, particularly acetylcholine and gastrin, respectively. These compounds directly engage with CCK-BR, leading to increased receptor activity and subsequent cellular responses. Dexloxiglumide, L-365,260, YM022, Loxiglumide, and Proglumide, classified as antagonists, indirectly enhance CCK-BR activity by preventing the inhibitory effects of endogenous cholecystokinin. These compounds block the inhibitory action of CCK, resulting in increased functional activity of CCK-BR.
Understanding the diverse mechanisms by which these compounds modulate CCK-BR provides insights into the intricate regulatory pathways governing this receptor. The selective activation of CCK-BR by these compounds highlights their potential as valuable tools in research aimed at deciphering the physiological roles of CCK-BR in various contexts, particularly in gastrointestinal functions and related processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Carbachol | 51-83-2 | sc-202092 sc-202092A sc-202092C sc-202092D sc-202092B sc-202092E | 1 g 10 g 25 g 50 g 100 g 250 g | $122.00 $281.00 $388.00 $683.00 $1428.00 $3060.00 | 12 | |
Carbachol, a cholinergic agonist, directly activates CCK-BR by mimicking the action of acetylcholine. It binds to muscarinic receptors, leading to the activation of intracellular signaling cascades that enhance CCK-BR functional activity. | ||||||
Pentagastrin | 5534-95-2 | sc-499379 | 1 mg | $235.00 | ||
Pentagastrin, a synthetic analogue of gastrin, directly enhances CCK-BR activity by binding to its receptor and initiating signaling events. Pentagastrin mimics the action of endogenous gastrin, leading to the activation of CCK-BR and subsequent modulation of physiological responses, particularly in the gastrointestinal tract. | ||||||
Bombesin | 31362-50-2 | sc-397365 | 1 mg | $81.00 | ||
Bombesin, a peptide with structural similarity to gastrin, directly enhances CCK-BR activity by binding to its receptor and triggering downstream signaling events. The interaction between Bombesin and CCK-BR leads to increased receptor activity, particularly in the context of gastrointestinal physiology. | ||||||
L-365,260 | 118101-09-0 | sc-311370 sc-311370A | 10 mg 50 mg | $161.00 $906.00 | 1 | |
L-365,260, a selective antagonist for CCK-BR, indirectly enhances receptor activity by preventing the inhibitory effects of endogenous cholecystokinin. By blocking the inhibitory action of CCK, L-365,260 leads to increased functional activity of CCK-BR, particularly in the context of gastrointestinal functions. | ||||||